HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burger, D. R. Articles by Finke, P. Search for Related Content PubMed Articles by Burger, D. R. Articles by Finke, P.

Nicotinamide: Suppression of Lymphocyte Transformation with a Component Identified in Human Transfer Factor

Surgical Research Laboratory, Veterans Administration Hospital, Portland, Oregon 97207, Department of Microbiology and Immunology, University of Oregon Health Sciences Center, Portland, Oregon 97201, Oregon Graduate Center, Beaverton, Oregon, and the Department of Surgery, University of Oregon Health Sciences Center, Portland, Oregon 97201

Abstract

The component in human transfer factor (TF) (Fraction IV, from exclusion chromatography on Sephadex G-25) responsible for suppression of antigen-induced lymphocyte transformation was previously identified as nicotinamide. Commercially available nicotinamide was subsequently shown to produce suppression of antigen-induced responses in vitro previously observed with TF Fraction IV. Nicotinamide was found to be nontoxic at the highest concentrations employed (10^-2 M) and suppressive over a relatively broad range (10^-5 to 10^-2 M). The suppression appeared to be related to the magnitude of antigen- or mitogen-induced transformation and was apparent even when nicotinamide was added as late as 48 hr after stimulant addition.

This article has been cited by other articles:

				M. R. NAMAZI Nicotinamide: a potential addition to the anti-psoriatic weaponry FASEB J, August 1, 2003; 17(11): 1377 - 1379. [Abstract] [Full Text] [PDF]

				E. Schmidt, K. Obe, E.-B. Brocker, and D. Zillikens Serum Levels of Autoantibodies to BP180 Correlate With Disease Activity in Patients With Bullous Pemphigoid Arch Dermatol, February 1, 2000; 136(2): 174 - 178. [Abstract] [Full Text] [PDF]